BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32196725)

  • 1. Optimal high-density lipoprotein cholesterol level for decreasing benign prostatic hyperplasia in men not taking statin medication: A historical cohort study.
    Yoo S; Oh S; Suh J; Park J; Cho MC; Jeong H; Won S; Son H
    Prostate; 2020 May; 80(7):570-576. PubMed ID: 32196725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impacts of metabolic syndrome and lifestyle on the prevalence of benign prostatic hyperplasia requiring treatment: historical cohort study of 130 454 men.
    Yoo S; Oh S; Park J; Cho SY; Cho MC; Jeong H; Son H
    BJU Int; 2019 Jan; 123(1):140-148. PubMed ID: 30125452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do cholesterol levels and continuity of statin use affect colorectal cancer incidence in older adults under 75 years of age?
    Han KT; Kim S
    PLoS One; 2021; 16(4):e0250716. PubMed ID: 33891657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men.
    Parsons JK; Bergstrom J; Barrett-Connor E
    BJU Int; 2008 Feb; 101(3):313-8. PubMed ID: 18005202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated Serum Non-HDL (High-Density Lipoprotein) Cholesterol and Triglyceride Levels as Residual Risks for Myocardial Infarction Recurrence Under Statin Treatment.
    Suzuki K; Oikawa T; Nochioka K; Miura M; Kasahara S; Sato M; Aoyanagi H; Shiroto T; Takahashi J; Miyata S; Sakata Y; Shimokawa H
    Arterioscler Thromb Vasc Biol; 2019 May; 39(5):934-944. PubMed ID: 30866657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia.
    Hammarsten J; Högstedt B
    Blood Press; 1999; 8(1):29-36. PubMed ID: 10412880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nationwide incidence and treatment pattern of benign prostatic hyperplasia in Korea.
    Lee YJ; Lee JW; Park J; Seo SI; Chung JI; Yoo TK; Son H
    Investig Clin Urol; 2016 Nov; 57(6):424-430. PubMed ID: 27847916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl.
    Posadas-Sánchez R; Posadas-Romero C; Mendoza-Pérez E; Caracas-Portilla NA; Cardoso-Saldaña G; Medina-Urrutia A; Jorge-Galarza E; Juárez-Rojas JG
    Am J Cardiol; 2012 Mar; 109(5):636-41. PubMed ID: 22169129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between statin adherence and cholesterol level reduction from baseline in a veteran population.
    Kazerooni R; Watanabe JH; Bounthavong M
    Pharmacotherapy; 2013 Oct; 33(10):1044-52. PubMed ID: 23744794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.
    Rył A; Rotter I; Grzywacz A; Małecka I; Skonieczna-Żydecka K; Grzesiak K; Słojewski M; Szylińska A; Sipak-Szmigiel O; Piasecka M; Walczakiewicz K; Laszczyńska M
    Int J Environ Res Public Health; 2017 Oct; 14(11):. PubMed ID: 29084161
    [No Abstract]   [Full Text] [Related]  

  • 11. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort.
    Kukko V; Kaipia A; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):373-378. PubMed ID: 29273728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study.
    Feng T; Howard LE; Vidal AC; Moreira DM; Castro-Santamaria R; Andriole GL; Freedland SJ
    Int J Urol; 2017 Feb; 24(2):151-156. PubMed ID: 28004415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan.
    Tseng CH
    BMC Cancer; 2013 Jan; 13():7. PubMed ID: 23286275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings.
    O'Connor PJ; Gray RJ; Maciosek MV; Fillbrandt KM; DeFor TA; Alexander CM; Weiss TW; Teutsch SM
    Prev Chronic Dis; 2005 Jul; 2(3):A05. PubMed ID: 15963307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer.
    Hammarsten J; Högstedt B
    Blood Press; 2004; 13(1):47-55. PubMed ID: 15083641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between triglyceride high density lipoprotein cholesterol ratio and benign prostate hyperplasia in non-diabetic patients:a cross-sectional study.
    Besiroglu H; Dursun M; Otunctemur A; Ozbek E
    Aging Male; 2017 Sep; 20(3):198-204. PubMed ID: 28332908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
    Ballantyne CM; Raichlen JS; Cain VA
    J Am Coll Cardiol; 2008 Aug; 52(8):626-32. PubMed ID: 18702965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome.
    Zhang X; Zeng X; Dong L; Zhao X; Qu X
    World J Urol; 2015 Dec; 33(12):2071-7. PubMed ID: 25850975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.